A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > COMMENTARY
COMMENTARY
- FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
- MHLW Grows Jittery over Supply Risks amid Rising Foreign Investments
September 8, 2025
- Pharmacies Reel from Pricey Drug Waste, Sparking Calls for Packaging Overhaul and Price Penalties
August 27, 2025
- As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce
August 5, 2025
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
July 18, 2025
- FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
July 4, 2025
- Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
- Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
May 27, 2025
- Impact of US Drug Policy: President Trump Shaking the World of Pharma
May 19, 2025
- New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
- How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
- Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
- Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
- Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
- Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…